Organogenesis
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 862
- Market Cap
- -
- Introduction
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 170
- Registration Number
- NCT06618612
- Locations
- πΊπΈ
Kent State University, College of Podiatric Medicine, Clevland, Ohio, United States
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 474
- Registration Number
- NCT06000410
- Locations
- πΊπΈ
Central Research Associates, Inc., Birmingham, Alabama, United States
πΊπΈAlabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
πΊπΈFiel Family & Sports Medicine, Tempe, Arizona, United States
Clinical Study Of Affinity Versus SOC In The Management Of VLUs
- Conditions
- Venous Leg Ulcer
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 200
- Registration Number
- NCT04901013
- Locations
- πΊπΈ
ILD Research, Carlsbad, California, United States
Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 474
- Registration Number
- NCT04636229
- Locations
- πΊπΈ
Central Research Associates, Birmingham, Alabama, United States
πΊπΈAlabama Clinical Therapeutics, Birmingham, Alabama, United States
πΊπΈAMR Mobile, Mobile, Alabama, United States
Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 200
- Registration Number
- NCT03855514
- Locations
- πΊπΈ
ILD Research Center, Carlsbad, California, United States
πΊπΈLimb Preservation Platform, Fresno, California, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Organogenesis ReNu Fails to Meet Primary Endpoint in Second Phase 3 Trial for Knee Osteoarthritis
Organogenesis announced that ReNu, a cryopreserved amniotic suspension allograft, did not achieve statistical significance for its primary endpoint in the second Phase 3 trial for knee osteoarthritis pain management.
ReNu Shows Promise in Phase 3 Trial for Knee Osteoarthritis
Organogenesis Holdings reports positive interim analysis from its Phase 3 trial of ReNu for knee osteoarthritis, covering 50% of 474 planned patients.